Takeaways: Novo Nordisk is defending branded Ozempic’s market share by narrowing the price gap with generic semaglutide for uninsured Canadians. That should help reduce switching to lower-cost a...
Takeaways Dr. Reddy’s is using this Canada launch to cement itself as an early global player in generic GLP‑1 injectables, showing it can move from approval to market in days and supply at ...
Takeaways Apo‑Semaglutide should put real downward pressure on Ozempic pricing in Canada and accelerate a shift of volume from the originator to generics, especially in publicly funded and emplo...
The Obesity Drug Gold Rush: Healthcare Breakthrough or Market Frenzy? The global pharmaceutical industry is witnessing an unprecedented surge in demand for obesity therapies, transforming what was onc...
Takeaways Apo‑Semaglutide should put real downward pressure on Ozempic pricing in Canada and accelerate a shift of volume from the originator to generics, especially in publicly funded and emplo...
Takeaways: Dr. Reddy’s has become the first company to secure Health Canada approval for a generic semaglutide injection (Ozempic equivalent), with an NOC covering 2 mg and 4 mg once‑weekly pens...
